AstraZeneca PLC
AZN
Company Profile
Business description
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
Contact
1 Francis Crick Avenue
Cambridge Biomedical Campus
CambridgeCB2 0AA
GBRT: +44 2037495000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
94,300
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,774.30 | 5.60 | -0.06% |
| CAC 40 | 7,558.16 | 57.83 | -0.76% |
| DAX 40 | 23,498.33 | 143.25 | -0.61% |
| Dow JONES (US) | 42,982.43 | 106.59 | -0.25% |
| FTSE 100 | 8,718.75 | 40.24 | -0.46% |
| HKSE | 24,357.56 | 117.11 | -0.48% |
| NASDAQ | 19,973.55 | 61.02 | 0.31% |
| Nikkei 225 | 39,482.29 | 540.22 | 1.39% |
| NZX 50 Index | 12,477.13 | 16.17 | 0.13% |
| S&P 500 | 6,092.16 | 0.02 | -0.00% |
| S&P/ASX 200 | 8,553.50 | 5.70 | -0.07% |
| SSE Composite Index | 3,459.66 | 3.68 | 0.11% |